Evidence map›Paper›PMID 9797726›Full record

ArticleJournal of clinical pathology1998

The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques.

E Sabattini, K Bisgaard, S Ascani, S Poggi, M Piccioli, C Ceccarelli, F Pieri, G Fraternali-Orcioni, S A Pileri

Abstract readComparative Study
In one paragraph

Article in Journal of clinical pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed.

  1. Trial
  2. Trial
  3. A Japanese encephalitis virus biological clone with anThe Journal of general virology · 2025
    Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Zonated quantification of immunohistochemistry in normal and steatotic livers.Virchows Archiv : an international journal of pathology · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

E SabattiniHaemolymphopathology, Unit, University of Bologna, Italy.
K Bisgaard
S Ascani
S Poggi
M Piccioli
C Ceccarelli
F Pieri
G Fraternali-Orcioni
S A Pileri

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess a newly developed immunohistochemical detection system, the EnVision++.

methodsA large series of differently processed normal and pathological samples and 53 relevant monoclonal antibodies were chosen. A chessboard titration assay was used to compare the results provided by the EnVision++ system with those of the APAAP, CSA, LSAB, SABC, and ChemMate methods, when applied either manually or in a TechMate 500 immunostainer.

resultsWith the vast majority of the antibodies, EnVision++ allowed two- to fivefold higher dilutions than the APAAP, LSAB, SABC, and ChemMate techniques, the staining intensity and percentage of expected positive cells being the same. With some critical antibodies (such as the anti-CD5), it turned out to be superior in that it achieved consistently reproducible results with differently fixed or overfixed samples. Only the CSA method, which includes tyramide based enhancement, allowed the same dilutions as the EnVision++ system, and in one instance (with the anti-cyclin D1 antibody) represented the gold standard.

conclusionsThe EnVision++ is an easy to use system, which avoids the possibility of disturbing endogenous biotin and lowers the cost per test by increasing the dilutions of the primary antibodies. Being a two step procedure, it reduces both the assay time and the workload.

Indexed as

Antibodies, MonoclonalBiomarkersBiomarkers, TumorCosts and Cost AnalysisEvaluation Studies as TopicHumansImmunohistochemistrySensitivity and SpecificityAntibodies, MonoclonalBiomarkersBiomarkers, Tumor

Identifiers

PMID9797726
PMCPMC500802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.